Tick-borne encephalitis vaccine clinical trials
How each study uses tick-borne encephalitis vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 13 Aug 2021 · Ticovac · BLA 125740 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- 9
Studies by the year they started
9 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses tick-borne encephalitis vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in ChildrenCompletedPhase 3PfizerNCT00840801Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedPhase 3PfizerNCT00161876Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedPhase 2PfizerNCT00161889Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedPhase 4PfizerNCT00503529Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedPhase 4PfizerNCT00161967Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedPhase 3PfizerNCT00161824Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedPhase 2/3PfizerNCT00161746Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedPhase 2PfizerNCT00161850Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedPhase 4PfizerNCT00161954Written as Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)